IACH Focus on Leukemia 2020 | Areas of further exploration in ALL
Christian Chabannon
• 1 Oct 2020
Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, discusses the challenges in defining the relative importance of CAR T-cell therapy to other innovative therapies under development for acute lymphoblastic leukemia (ALL), such as bispecific antibodies. Further exploration is also needed to introduce the systematic use of minimal residual disease (MRD) to justify medical decisions. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
Disclosures
Sanofi SA, Kite / Gilead, Novartis, Celgene / BMS, Janssen, Bellicum Pharmaceuticals, Terumo BCT: speakers bureau & advisory boards
